Pharming Group N.V. (PHAR) Cash & Current Investments (2019 - 2024)

Pharming (PHAR) has disclosed Cash & Current Investments for 3 consecutive years, with $207.3 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Cash & Current Investments rose 8.03% year-over-year to $207.3 million, compared with a TTM value of $207.3 million through Dec 2022, up 8.03%, and an annual FY2022 reading of $207.3 million, up 8.03% over the prior year.
  • Cash & Current Investments was $207.3 million for Q4 2022 at Pharming, up from $191.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $207.3 million in Q4 2022 and bottomed at $191.9 million in Q4 2021.
  • Average Cash & Current Investments over 3 years is $199.5 million, with a median of $199.2 million recorded in 2020.
  • The sharpest move saw Cash & Current Investments dropped 3.65% in 2021, then rose 8.03% in 2022.
  • Year by year, Cash & Current Investments stood at $199.2 million in 2020, then dropped by 3.65% to $191.9 million in 2021, then increased by 8.03% to $207.3 million in 2022.
  • Business Quant data shows Cash & Current Investments for PHAR at $207.3 million in Q4 2022, $191.9 million in Q4 2021, and $199.2 million in Q4 2020.